This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest in Walgreens Boots Stock Now
by Zacks Equity Research
Walgreens Boots (WBA) gains from tie-ups. The company's alliance with Express Scripts encourages.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.
Stay-at-Home Stocks Find Favor With New Age Investors
by Urmimala Biswas
Gradually changing lifestyle of people indicates that they are keen on staying indoors and availing products and services that are delivered to them.
Why Walgreens (WBA) Could Beat Earnings Estimates Again
by Zacks Equity Research
Walgreens (WBA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharmacies and Drug Stores Stock Outlook: Prospects Bright
by Zacks Equity Research
Amazon's entry into drug distribution is expected be a game changer but the immediate implications will be limited, given that the healthcare space is highly complex and regulated.
Bear of the Day: Sally Beauty Holdings (SBH)
by Ryan McQueeney
Avoid this retailer with a history of under-performance.
How Will Rite Aid Be Impacted by Albertsons Deal Termination?
by Zacks Equity Research
Rite Aid (RAD) and Albertsons mutually terminate their pending merger deal. Currently, Rite Aid is on track to leverage on its growth strategies as a standalone company.
Buy Amazon (AMZN) Stock On Possible Gas Station & Travel Push?
by Benjamin Rains
Shares of Amazon (AMZN) popped Tuesday after D.A. Davidson analysts suggested that the next logical industries for the e-commerce giant to enter would be gas stations and travel. Amazon could likely jump into the gas station market without much fuss, similar to Costco (COST), and certainly has the online infrastructure and customer base to offer travel deals. But what should investors make of this?
Rite Aid Stock Falls on FY19 View Cut Ahead of Merger Vote
by Zacks Equity Research
Rite Aid (RAD) lowers fiscal 2019 guidance as the generic drug purchasing efficiencies fall below expectations. Rite Aid shareholders are likely to vote for the Albertsons merger on Aug 9.
Why Amazon (AMZN) Stock Is A Strong Buy Right Now
by Benjamin Rains
Nearly everyone knows that Amazon (AMZN) stock has been one of the hottest on Wall Street for years. Yet some assume now is too late to get in on the fun, which simply isn't true. So let's take a look at why investors should buy Amazon stock right now following yet another quarter of stellar growth.
Dow 30 Stock Roundup: Goldman Sachs, IBM, J&J, Microsoft Earnings Impress
by Swarup Gupta
The index posted impressive gains this week, boosted by a strong economy and expectations of robust earnings.
Stock Market News For Jul 16, 2017
by Zacks Equity Research
Markets closed higher on Friday, with the S&P 500 posting its highest close in more than five months.
Buy Walgreens (WBA) Stock Because It's Cheap & Amazon Fears Are Overblown?
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) are down 16.5% over the last year based mostly on Amazon (AMZN) fears. There is no doubt that online selling and delivery have altered the retail world, but does that mean Walgreens can no longer compete? Let's dive into some of WBA's fundamentals to see what to do with the stock.
Walgreens Boots (WBA) Grows on New Pacts Amid Several Woes
by Zacks Equity Research
Walgreens Boots' (WBA) alliance with Express Scripts is expected to expand both companies' existing group purchasing efforts.
Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review
by Swarup Gupta
The Dow traverses a holiday-shortened week during which trading volumes remain low.
Rite Aid (RAD) Stock Picks Momentum: Will It Scale Higher?
by Zacks Equity Research
Rite Aid (RAD) gathers momentum on pending merger with Albertsons, the sale of assets to Walgreens, lesser debt burden and a robust outlook.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
Will Healthcare Buck Up on Amazon's Pillpack Takeover Deal?
by Sapna Bagaria
Amazon's (AMZN) use of technology, innovative strategies and skilled leadership should take it far in the healthcare space.
NKE Beats Earnings, Spotify's Video Push, & AMZN's Big Pharma Purchase
by Madeleine Johnson
On today's episode of the Zacks Friday Finish Line, Editor Maddy Johnson is joined by Ben Rains, an Associate Stock Strategist here at Zacks, to take on this week's biggest stories, including Nike's latest quarterly earnings results, Spotify's media ambitions, and Amazon's latest assault on the healthcare industry.
Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress
by Swarup Gupta
The Dow endured a turbulent week, marked by lingering trade tensions.
After a Historic Rise, Should You Still Buy Amazon (AMZN) Stock?
by Afrasiab Mian
With massive growth already baked into its stock price, many investors may feel that Amazon stock is too expensive and that they have missed their chance to cash in. Is this truly the case? Let's take a look.
Investors Shouldn't Panic About Amazon's PillPack Purchase
by Benjamin Rains
Shares of pharmacy giants CVS (CVS), Rite Aid (RAD), and Walgreens Boots Alliance (WBA) all plummeted on Thursday morning after Amazon (AZMN) announced its purchase of online pharmacy delivery startup PillPack. The move clearly has some investors worried that Amazon's push into the pharmaceutical industry will hurt the current powers. So let's take a look at more of the details to find out what's really going on.
Walgreens (WBA) Tops Q3 Earnings Estimates, Narrows View
by Zacks Equity Research
Walgreens Boots (WBA) is upbeat about the recent acquisition of stores from Rite Aid which has already started to strengthen its U.S. pharmacies business.
WBA Enters The Dow, Q1 GDP Disappoints
by Zacks Equity Research
WBA Enters The Dow, Q1 GDP Disappoints
Walgreens Stumbles onto Dow, Futures Down
by Mark Vickery
We see negative sentiment for Walgreens based on news this morning that Amazon (AMZN) is buying its way into the retail pharma space.